Results of Angelini et al. [11] suggest that polymorphisms in the genes coding folate-metabolising enzymes may modify the risk of GIST and clinical outcome and results of Haller et al. [28] suggest SPP1 promoter methylation as a novel and independent prognostic parameter in GIST. Here, SPP1 is linked to gastrointestinal stromal tumor.